Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neuroderm Ltd Ord Sh (NDRM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,023,698
  • Shares Outstanding, K 26,350
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,500 K
  • 36-Month Beta 0.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.98
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.56
  • Most Recent Earnings -0.25 on 05/11/17
  • Next Earnings Date 11/09/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.80 +0.13%
on 09/19/17
38.95 -0.26%
on 10/17/17
unch (unch)
since 09/15/17
3-Month
30.70 +26.55%
on 07/18/17
38.95 -0.26%
on 10/17/17
+7.60 (+24.32%)
since 07/17/17
52-Week
15.20 +155.59%
on 12/01/16
38.95 -0.26%
on 10/17/17
+21.50 (+123.92%)
since 10/17/16

Most Recent Stories

More News
Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced today the completion of the previously announced...

NDRM : 38.85 (-0.13%)
MTZPY : 23.4700 (+0.62%)
NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced that at NeuroDerm's extraordinary general...

NDRM : 38.85 (-0.13%)
MTZPY : 23.4700 (+0.62%)
Viceroy Research Believes Mitsubishi Tanabe's $1.1B Acquisition of Neuroderm Will Result in Complete Writeoff

Viceroy Research (Viceroy) today released a detailed analysis of Mitsubishi Tanabe's (TYO: 4508) potential acquisition of Neuroderm (NASDAQ: NDRM). Viceroy has meticulously researched the...

NDRM : 38.85 (-0.13%)
NeuroDerm Announces Extraordinary General Meeting of Shareholders to Approve Acquisition by Mitsubishi Tanabe Pharma Corporation

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will hold an extraordinary...

NDRM : 38.85 (-0.13%)
MTZPY : 23.4700 (+0.62%)
Biotech Sector Continued Resurgence Fueled by Increasing Clinical Trial Activity & Business Friendly FDA Leadership

PALM BEACH, Florida, July 25, 2017 /PRNewswire/ --

GNCA : 1.46 (unch)
NDRM : 38.85 (-0.13%)
RETA : 32.96 (+0.49%)
NVAX : 1.04 (-1.05%)
MBRX : 2.17 (-0.36%)
NeuroDerm (NDRM) Catches Eye: Stock Gains 15.5% in Session

NeuroDerm Ltd. (NDRM) moved last session, as its shares rose over 15% on the day.

NDRM : 38.85 (-0.13%)
RTTR : 0.36 (-3.73%)
Results of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology

-Complete reduction of OFF-time to zero in 42% of patients treated for 24 hours; statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients ON by...

NDRM : 38.85 (-0.13%)
Expansion of Global Clinical Trials for Treating an Array of Rare Diseases Boosting Market Growth

PALM BEACH, Florida, June 15, 2017 /PRNewswire/ --

VRX.TO : 15.35 (+0.13%)
NDRM : 38.85 (-0.13%)
VRX : 12.14 (+0.08%)
EPZM : 17.00 (-0.29%)
OMER : 18.70 (-1.32%)
MBRX : 2.17 (-0.36%)
NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson's Disease and Movement Disorders

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will present six posters related...

NDRM : 38.85 (-0.13%)
European Medicines Agency Accepts Design of NeuroDerm's ND0612 Phase III iNDiGO Efficacy Trial

NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it has received a Scientific Advice...

NDRM : 38.85 (-0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H...

See More

Support & Resistance

2nd Resistance Point 38.98
1st Resistance Point 38.92
Last Price 38.85
1st Support Level 38.82
2nd Support Level 38.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart